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Background: Several initiatives have assessed if mining electronic health records
(EHRs) may accelerate the process of drug safety signal detection. In Europe, Exploring
and Understanding Adverse Drug Reactions (EU-ADR) Project Focused on utilizing
clinical data from EHRs of over 30 million patients from several European countries.
Rofecoxib is a prescription COX-2 selective Non-Steroidal Anti-Inflammatory Drugs
(NSAID) approved in 1999. In September 2004, the manufacturer withdrew rofecoxib
from the market because of safety concerns. In this study, we investigated if the signal
concerning rofecoxib and acute myocardial infarction (AMI) could have been identified in
EHR database (EU-ADR project) earlier than spontaneous reporting system (SRS), and
in advance of rofecoxib withdrawal.
Methods: Data from the EU-ADR project and WHO-VigiBase (for SRS) were used
for the analysis. Signals were identified when respective statistics exceeded defined
thresholds. The SRS analyses was conducted two ways- based on the date the AMI
events with rofecoxib as a suspect medication were entered into the database and also
the date that the AMI event occurred with exposure to rofecoxib.
Results: Within the databases participating in EU-ADR it was possible to identify a
strong signal concerning rofecoxib and AMI since Q3 2000 [RR LGPS = 4.5 (95% CI:
2.84–6.72)] and peaked to 4.8 in Q4 2000. In WHO-VigiBase, for AMI term grouping, the
EB05 threshold of 2 was crossed in the Q4 2004 (EB05 = 2.94). Since then, the EB05
value increased consistently and peaked in Q3 2006 (EB05 = 48.3) and then again in Q2
2008 (EB05 = 48.5). About 93% (2260 out of 2422) of AMIs reported in WHO-VigiBase
database actually occurred prior to the product withdrawal, however, they were reported
after the risk minimization/risk communication efforts.
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Conclusion: In this study, EU-EHR databases were able to detect the AMI signal
4 years prior to the SRS database. We believe that for events that are consistently
documented in EHR databases, such as serious events or events requiring in-patient
medical intervention or hospitalization, the signal detection exercise in EHR would be
beneficial for newly introduced medicinal products on the market, in addition to the
SRS data.
Keywords: EU-ADR, WHO-VigiBase, signal detection, EHR, LGPS
INTRODUCTION
Rofecoxib is a prescription COX-2 selective Non-Steroidal
Anti-Inflammatory Drugs (NSAID) for relief of osteoarthritis
signs and symptoms, management of acute pain in adults and
treatment of menstrual pain. The European Medicines Agency
(EMA) and the United States Food and Drug Administration
(FDA) provided approval for rofecoxib in 1999. In June 2000,
Vioxx Gastrointestinal Outcome studies (VIGOR) was submitted
to FDA which demonstrated an increased risk of cardiovascular
thrombotic events, mostly driven by heart attacks (0.5 vs.
0.1% for rofecoxib and naproxen, respectively) (Food and
Drug Administration, 2017). However, this finding was initially
surprisingly attributed to cardio-protective effect of naproxen. In
April 2002, this and other cumulated evidence on potential risks
associated to rofecoxib led to the introduction of warnings on
rofecoxib labeling concerning the increased risk of cardiovascular
events (heart attack and stroke) (Ball et al., 2016; Food and Drug
Administration, 2016). Subsequently, in September 2004, the
APPROVe study showed increased risk of myocardial infarction
and stroke for the 12.5 and 25 mg dose as compared to placebo
after 18 months of treatment (Food and Drug Administration,
2017). The same month, the manufacturer withdrew rofecoxib
from the market because of concerns about increased risk
of heart attack and stroke associated with long-term, high-
dosage use (Ritter et al., 2009; Food and Drug Administration,
2017). Subsequent to rofecoxib finding, there has been extensive
research done on NSAIDs and cardiovascular risks.
This case triggered dialog in the scientific community
about how to improve the post-marketing surveillance of
medicines with the aim of achieving early signal detection
and ultimately regulatory intervention to ensure patients’
safety (Ritter et al., 2009). In particular, several initiatives
have assessed if mining electronic health records (EHRs) may
accelerate the process of drug safety signal detection and
strengthening. In the United States (US), in 2008, FDA has
created the Sentinel System which is a national electronic
system for medicinal product safety surveillance (Sentinel,
2017). As of 2016, the Sentinel Distributed Database contained
medical and pharmacy benefits data on 178 million members
(Sentinel, 2017). Also in 2008, in the United States, a
public-private initiative called formerly Observational Medical
Outcomes Partnership (OMOP) and currently Observational
Health Data Sciences and Informatics (OHDSI) was established
to research and educate stakeholders on the appropriate
use of EHR for studying the effects of medicines (OMOP,
2017).
In Europe, Exploring and Understanding Adverse Drug
Reactions (EU-ADR) Project Focused on using clinical data
from EHRs of over 30 million patients from several European
countries (Netherlands, Denmark, United Kingdom, and Italy)
during 2008–2012 (Coloma et al., 2011). The EU-ADR analyses
has showed that signal detection using EHR could complement
spontaneous reports that remain the cornerstone of drug safety
signal detection, particularly with events occurring at high
frequency in the general population and those that are perceived
as unlikely to be drug induced (Pacurariu et al., 2015; Patadia
et al., 2015a). A retrospective study of EHR in the EU-ADR
project demonstrated the value of using EHR data in signal
detection and strengthening (Pacurariu et al., 2015; Patadia et al.,
2015b).
In the current study we aimed to explore if the signal
concerning rofecoxib and acute myocardial infarction (AMI)
could have been identified in the EU-ADR distributed healthcare
database project earlier than the spontaneous reporting system
(SRS) and contribution of EU-ADR data in signal strengthening
and possibly earlier rofecoxib withdrawal.
MATERIALS AND METHODS
Data Sources
For this study, data from the EU-ADR project and the World
Health Organization’s VigiBaseTM (WHO-VigiBase) which is
an international spontaneous reporting database were used for
the analysis. The EU-ADR project comprised seven established
European healthcare databases located in four countries. Health-
Search (HSD; Italy), Integrated Primary Care Information (IPCI;
Netherlands), and Pedianet (Italy) are primary care databases,
where both clinical information including medical diagnoses
and drug prescriptions are recorded by general practitioners
(IPCI and HSD) or family pediatrician (Pedianet) distributed all
over the respective countries. The Aarhus University Hospital
Database (Aarhus, Denmark), PHARMO (Netherlands), and
the regional Italian databases of Lombardy and Tuscany are
comprehensive record-linkage systems in which drug dispensing
data of well-defined populations is linked to a registry of
hospital discharge diagnoses and other registries collecting
clinical information. The main characteristics of the EU-ADR
project have been described in more detail by Coloma et al. (2011,
2012). The data collected between the years 1995–2010 were used
in this study (Coloma et al., 2012).
For the SRS analysis, the WHO-VigiBase database was used.
This database consists of reports of suspected adverse drug
Frontiers in Pharmacology | www.frontiersin.org 2 June 2018 | Volume 9 | Article 594
fphar-09-00594 June 4, 2018 Time: 20:48 # 3
Patadia et al. Signal Detection Using EHR Databases
reactions (ADRs) received since 1968 from more than 100
member countries. At the time of this analysis, it contained over
nine million reports of ADRs worldwide till 2010 (WHO, 2016).
The reports originate from various sources including healthcare
professionals, consumers, and pharmaceutical manufacturers.
The suspected ADRs are coded using the Medical Dictionary
for Regulatory Activities (MedDRA) and patient narratives
(event history and details) are not included in the public
version.
AMI Search Criteria
Due to the large heterogeneity in event coding between
EHR databases in the EU-ADR data, harmonization of
event definition was required. The Unified Medical Language
System R© (UMLS R©) concepts and related codes and labels
corresponding to AMI were identified, and using these codes
and terms, database owners constructed their queries for the
data extraction. The queries for the event data extraction
from different EHR databases were analyzed by a team of
clinical experts and, where necessary, were harmonized across
all EHR databases. The detailed process is described by
Avillach et al. (2010, 2013).
For the analyses in the WHO-VigiBase databases, the
MedDRA dictionary including Standardized MedDRA Queries
[version 11.1] was reviewed to define custom grouping of terms
for AMI which included the following preferred terms: ‘Acute
myocardial infarction,’ ‘ECG signs of myocardial ischemia,’ ‘Silent
myocardial infarction.’
Rofecoxib-AMI Association Evaluation
In the EU-ADR project, the Longitudinal Gamma Poisson
Shrinker (LGPS), the posterior expectation of the incidence
rate ratio [Relative Risk (RR)-LGPS] was developed and
estimated for drug-event pair. A RR-LGPS ≥ 2 (p-value < 0.05)
was classified as a signal, except when the “Longitudinal
Evaluation of Observational Profiles of Adverse events
Related to Drugs” (LEOPARD) method identified such an
association as potentially due to protopathic bias (Gerhard,
2008; Schuemie, 2011; Schuemie et al., 2012). The relative
risks of AMI during exposure to rofecoxib as compared to
non-exposure to the drug was calculated on quarter of year
basis by measuring LGPS values, WHO-VigiBase analyses
were conducted on data up to and including 4th quarter
of 2010 using Oracle EmpiricaTM Signal (Waltham, MA,
United States). The Gamma Poisson Shrinker (GPS) was
used to compute EB05 (Empirical Bayes posterior Gamma
Mixture 5th percentile; estimates lower point in 90% confidence
interval). A threshold of EB05 ≥ 2 (p-value < 0.05) was
selected based on extensive use and validation in PV practice
(Szarfman et al., 2002). The analyses were conducted two
ways- based on the date the AMI events with rofecoxib
as a suspect medication were entered into the WHO-
VigiBase database and also the date that the AMI event
occurred with respect to the exposure to rofecoxib. The data




A total of 685 AMI events during exposure to rofecoxib were
captured in the databases participating in the EU-ADR project
during the years 2000–2010 (Figure 1). The first AMI event
during rofecoxib was recorded in third quarter of the year 2000
with total of 49 AMIs for the rest of that year. After withdrawal
of rofecoxib there have not been any new AMI events during
exposure, since 2005.
The rofecoxib market penetration in person-years of exposure
in the participating EU databases is shared in Figure 2. Rofecoxib
uptake began in the second quarter of the year 2000 with
approximately 5,562 person-years of exposure in the year 2000.
Its quarter-by-quarter exposure peaked in the first quarter of
2004 with 8,959 person-years of exposure. Subsequent to that, the
exposure rapidly declined throughout 2004.
The databases in the EU-ADR project were able to identify a
strong association concerning rofecoxib and AMI since the third
quarter of 2000 (RR LGPS = 4.5; 95% Confidence Interval: 2.84–
6.72) (see Figure 3). The threshold of RR LGPS> = 2 was crossed
early in 2000. The RR LGPS value increased to 4.5 in the third
quarter of 2000 and peaked to 4.8 in the fourth quarter of 2000.
The RR LGPS value ranged between 3 and 4 in the year 2001
and between 2 and 3 in the year 2002. It subsequently stabilized
around 2 and stayed above the threshold of 2 until 2005.
WHO-VigiBase Analysis
In the WHO-VigiBase SRS database, a total of 2,422 reports
of AMIs were received with rofecoxib as a suspect medication.
Figure 4 shows the WHO-VigiBase data on rofecoxib and AMI
per quarter by the date data were reported and entered in the
WHO-VigiBase database. The first report of AMI with rofecoxib
as a suspect medication was submitted in the fourth quarter of
2003, after the initial warning in 2002. There were two large
increases in the number of new reports that were observed in
the third quarter of 2006 and the second quarter of 2008. The
EB05 threshold of 2 was crossed in the fourth quarter of 2004
(EB05 = 2.94). Since then, the EB05 value increased consistently
and peaked in the third quarter of 2006 (EB05 = 48.3) and then
again in second quarter of 2008 (EB05 = 48.5). It declined slightly
after 2008 but still stayed in the range of 40–45.
Figure 5 shows the WHO-VigiBase data on rofecoxib and
AMI per quarter by the date data were entered in the WHO-
VigiBase database (data load date) and also the date that the actual
event occurred (data mining quarter date). The data from this
chart shows that 93% (2,260 out of 2,422) of acute myocardial
events actually occurred prior to the product withdrawal.
However, they were reported after the risk minimization/risk
communication efforts.
DISCUSSION
We demonstrated in this study that the AMI signal concerning
rofecoxib could have been detected in the year 2000 (or 2001
at latest, taking into account the lag time in getting access to
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FIGURE 1 | Frequency of acute myocardial infarction (AMI) events occurring during exposure to rofecoxib in the EU-ADR database network.
FIGURE 2 | Rofecoxib exposure (person-years) cumulated over time in the EU-ADR database network.
large database network) using the EU-ADR network of claims
databases and EMRs, about 4 years before the signal was
identified in the SRS data. The signal was not identified earlier in
the WHO-VigiBase SRS. This is noteworthy since the association
of AMI and rofecoxib was already documented in the VIGOR
trial in which the finding on threefold increased cardiotoxicity
in rofecoxib users vs. naproxen users was misinterpreted as
protective effect of the latter drug (Juni et al., 2004).
For the past six decades, for the marketed medicinal products,
using spontaneously reported adverse events data has been the
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FIGURE 3 | Relative risk of AMI associated to rofecoxib use vs. non-use over time in the EU-ADR database network. Relative risk (RR) was measured as
Longitudinal Gamma Poission Shrinkage (LGPS) value together with 95% confidence interval.
FIGURE 4 | Distribution of reports of AMI for which rofecoxib was the suspected drug as collected over time in the WHO- VigiBase spontaneous reporting database.
EB05: Empirical Bayes posterior Gamma Mixture 5th percentile; estimates lower point in 90% confidence interval.
“gold standard” in the pharmacovigilance practice, even though,
the limitations of these data are well-recognized, including
under-reporting in general and also over-reporting of highly
publicized drug-adverse effects.
Healthcare professionals may not properly and readily
attribute the onset of a multifactorial event like AMI to
a medicine especially if that medicine is used for treating
a disease which is per se a strong cardiovascular risk
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FIGURE 5 | Acute myocardial infarction and Rofecoxib in WHO-VigiBase database. The yellow bars in the figure show the number of cumulative reports by quarter
using the data mining quarter date. The orange bats represent the cumulative reports by the date they were reported and entered into WHO-VigiBase. The vertical
blue line marks the date the manufacturer withdraw the product. The EBOS values using the data mining quarter is shown in greenline and using the data load
quarter is shown in red line.
factor as it is the case for rheumatology diseases requiring
coxib treatments. In the WHO-VigiBase database, initially,
extremely low number of reports of suspected rofecoxib-
associated AMI was reported. As a paradox, in the years
following the rofecoxib withdrawal, a huge increase in the
number of reports was observed. Data show that 93% of
the reports concerned AMIs that occurred prior to the initial
risk communications, however, was reported only after the
rofecoxib was withdrawn from the market. These data show
that the publicity of this topic was the driving force behind the
increase number of reports observed after a risk was identified
and not the true increase in the incidence of the drug-event
combination.
It is possible, that once the risk was confirmed, communicated,
and action taken by a regulatory agency, possibly healthcare
professionals felt supported or even validated, in some instances,
to report. In some cases, perhaps healthcare professional were
even feeling compelled to report once a risk communication
was distributed. Another major phenomenon to consider
is that legal actions are common in North America, once
a risk is communicated to public. Is the ‘encouragement’
from the lawyers driving patients and/or health care
professionals to recall and report AMIs retrospectively?
It will be interesting to tease out these reasons in future
research.
Electronic health record data are more immune to this
type of reporting bias. The data are collected as a by
product of the healthcare delivery practice and medical
records system. They are not dependent on a healthcare
professional or patient to, first, identify such an event and
then report the event. The collection of the events and
outcomes is less or not at all influenced by media or legal
actions. Although not all events and outcomes are consistently
captured in the EHR databases, serious events, such as
AMI, have a greater chance to be collected and accurately
coded.
As mentioned earlier, the SRS databases are used as a
“gold-standard” in the pharmacovigilance practice for marketed
products. However, the increased number of ADRs in the
SRS after identification and communication of a risk brings
minimal value to pharmacovigilance scientists. In fact, they
contribute to “noise” in the SRS database. It is important
for the pharmacovigilance scientists to understand this
phenomenon when they are conducting data mining and
signal detection for same medical concept but in different
marketed product.
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It is important to note limitations of this study. First, the
study focused only on AMI as adverse event associated to
with rofecoxib. As a consequence, the findings may not be
generalizable to a broader range of drug-event associations,
especially non-serious events which may not be captured
consistently in the EHR system or drugs which are used in
different therapeutic areas as compared to rofecoxib. In addition,
WHO-VigiBase data were used for the SRS analyses. There
are several other SRS databases that are widely used in the
pharmacovigilance practice. The results may not be generalizable
to other SRS databases. Another limitation is the fact that
the LGPS method used on EHR data does not correct for
confounding (Lawrence Gould, 2014), and the increase observed
might therefore reflect bias rather than a true signal. Lastly, true
timing of the detection of AMI-rofecoxib association has to take
into account the lag time between data generation and data access
which may delay of 6 months or even 1 year the association
identification in prospective evaluation. Future research should
focus on these issues.
CONCLUSION
In this EU database network study covering a source population
of 30 million persons, we were able to detect the AMI-rofecoxib
association around 4 years prior to the drug withdrawal. If such
a network was in place at that time it may have theoretically
speed up the process leading to rofecoxib removal from the
market. More specifically, the AMI-rofecoxib signal was initially
identified in RCT but misinterpreted. As Platt stated in the
Institute of Medicine meetings, large EHR and claims database
networks may complement SRS and other sources for post-
marketing drug safety evaluation, especially for those adverse
events which are frequently captured in EHR databases and are
not likely to be reported to SRS (Patadia et al., 2015a). The
United States implemented Sentinel and the Canadian Network
for Observational Drug Effect Studies (CNODES) has expanded
capacity for drug safety surveillance. The EU has implemented
several projects; however, none with sustainable system yet exist.
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